Articles tagged with Metastasis
Researchers found that the loss of caspase-8 protein promotes neuroblastoma metastasis by allowing cancer cells to break away from the primary tumor and spread to other sites in the body. Novel treatments that restore the tumor-suppression role of caspase-8 may prevent metastases and improve patient outcomes.
Researchers have identified a gene called caspase 8 that plays a crucial role in preventing tumor cells from metastasizing, or spreading to distant sites. By activating this mechanism, the researchers aim to develop targeted therapies to halt the spread of neuroblastoma and possibly other cancers.
A study found that nearly half of patients treated with the PC combination experienced a clinical benefit, including stable disease and tumor size reduction. Researchers believe this combination has a beneficial role, especially for patients with poor treatment outcomes.
Researchers have discovered that transforming growth factor beta (TGF-ß) regulates bone matrix properties, which affect bone elasticity, toughness, and resistance to fracture. The study suggests that targeting TGF-ß signaling could improve bone quality, potentially preventing osteoporosis and improving bone repair.
Cancer cells hybridize with macrophages to exhibit traits such as migration and blood supply formation. The study provides new insights into metastasis, a process previously attributed to tumor cell fusion.
A new study in mice found that chronic stress and UV radiation suppress the immune system, leading to increased tumor formation and quicker disease progression. Researchers observed suppression of T-cell function and type 1 cytokines, highlighting the potential for chronic stress to increase cancer risk.
ZBP1 guides actin messenger RNA to cell periphery and regulates translation into protein. The enzyme Src adds a phosphate group to ZBP1, unlocking the mRNA for translation into actin protein. This discovery could lead to new cancer therapies by targeting ZBP1 expression.
Researchers discovered AKT paradoxically blocks cancer cell motility and invasion abilities, preventing cancer spread. The study's findings suggest targeting AKT may increase cells' properties of motility and invasiveness.
Researchers developed a model that reprograms benign skin cells to express genes associated with aggressive melanoma cells, highlighting the role of tumor cell microenvironment in transformation. The study provides potential therapeutic strategies to inhibit melanoma spread.
Researchers at Northwestern University have discovered a potential target for preventing metastatic melanoma, the cancer's ability to spread and be fatal. The study identified focal adhesion kinase (FAK) as a key player in promoting aggressive melanoma behavior.
A recent study examined mortality and complications within 30 days following radical prostatectomy in 11,010 men who underwent the surgery between 1990 and 1999. The study found that age was associated with an increased risk of 30-day mortality, but the absolute risk of death was low even among men ages 70 to 79.
Treating four or more brain tumors with radiosurgery is safe and effective, translating to a survival benefit of up to 18 months for some patients. The study's findings suggest that tumor volume rather than the number of brain metastases should be used as a criterion for radiosurgery.
Scientists have identified a new compound in cranberries that prevents cancer cells from breaking away and spreading to other parts of the body. The compound inhibits the growth of human lung, colon, and leukemia cells in culture without affecting healthy cells.
Researchers discovered that a specific gene variant can arise as a mutation during cancer development, contributing to tumor growth and spread. The study found the variant in nearly half of liver metastatic tumors, suggesting it may be an important target for new therapies.
The study found two relapse peaks after surgery for breast cancer, with 20% of premenopausal patients relapsing within 10 months. Calculations predict that surgery-induced angiogenesis accelerates disease by two years and produces early deaths among screened young women.
Scientists at The Wistar Institute have identified the cancer gene MYC as activating the metastasis gene MTA1, a key regulator of tumor spread. Blocking this pathway may prevent metastasis and inform the development of new therapies.
Researchers at Sunnybrook Hospital have developed a unique mouse model that enables scientists to study how breast cancer spreads. By analyzing the genetic makeup of tumour cells, they hope to predict which tumours will metastasize and develop new treatments.
Researchers found RhoC essential for tumor metastasis, but dispensable for embryonic development and tumor initiation. RhoC-deficient mice display reduced tumor metastasis, lower cell motility, and survival properties in secondary sites.
Researchers at UNC have discovered that CIB1 inhibits cell migration in cancer cells by activating PAK1, a kinase that adds phosphate groups to other proteins. This finding suggests that CIB1 may be a potential target for developing new treatments to decrease tumor metastasis.
Researchers at Penn will employ a range of cellular and molecular imaging techniques to analyze genetically engineered mouse models of breast cancer. The goal is to understand the mechanisms underlying breast-cancer progression and develop more effective therapies against aggressive forms of this disease.
A population-based case control study found that PSA screening of asymptomatic men significantly reduces the risk of metastatic prostate cancer. The researchers discovered a 35% protective effect, even among men not screened regularly.
Christine Chung, a Vanderbilt researcher, has won the Damon Runyon Research Foundation/Lilly Clinical Investigator Award to support her work on genetic profiling for head and neck cancers. The award will provide funding for DNA microarray technology to predict tumor recurrence and response to chemotherapies.
Increased expression of claudin-1 has been found in human primary colon carcinomas and metastases. Claudin-1's mislocalization is associated with higher levels of expression and increased metastatic behavior in colon cancer cells.
A new study finds that oral capecitabine plus oxaliplatin shows comparable efficacy and toxicity profiles to traditional intravenous chemotherapy, offering a more convenient treatment option for patients. The regimen has shown similar response rates and overall survival, with benefits in terms of patient autonomy and quality of life.
Researchers identified an 11-gene BMI-1-pathway signature that consistently predicts disease recurrence, metastasis, and death after therapy in cancer patients. The presence of this gene expression pathway is associated with a high probability of poor therapy outcome and metastasis.
A new study found that phenotypic and functional qualities of T cells are associated with the ability to regress large tumors. Naïve and early effector T cells were more effective for tumor treatment than more differentiated T cells. This discovery is important for developing improved adoptive immunotherapy approaches.
A randomized trial of 900 patients with breast or prostate cancer found that a shorter course of radiation therapy was as effective as the standard treatment in providing pain relief. The study also showed less acute toxicity and re-treatment rates in patients who received a single dose of 8 Gy radiation.
Research on the ATM gene suggests that women carrying one mutated copy are twice as likely to develop breast cancer, with a lifetime risk of one in six compared to one in 11 in the general population. Meanwhile, a new study on ursodeoxycholic acid treatment found a 39% reduction in colorectal adenoma recurrence among patients who recei...
Researchers developed a mouse model that closely mimics human pancreatic cancer at multiple levels, including clinical presentation and histological changes. The model demonstrates distinct similarities to human pancreatic cancer, including metastasis to the liver and lungs.
Researchers have developed a whole-body MRI technique that can scan patients' entire bodies in under 20 minutes for cancer spread to bone, detecting 100% of cases. This method offers better sensitivity and specificity than other methods, making it a promising tool for non-invasive cancer diagnosis.
Researchers have found molecular changes in breast cancer that are similar to those occurring in brain tumors, providing new insights into disease progression and potential treatment targets. The study identified specific laminin isoform changes that coincide with blood vessel growth and metastasis in breast cancer.
Bone SPECT outperforms FDG PET in detecting breast cancer metastases, with a sensitivity of 85% and accuracy of 96%. PET's limitations make it less effective in revealing certain types of lesions.
Research at Massachusetts General Hospital found that tumor cells use VEGF-A to stimulate growth of new lymphatic vessels, allowing them to spread to lymph nodes more easily. The study's results suggest that targeting this process could be a promising approach for preventing the further spread of metastatic cancer.
Researchers develop Fluorform-Assisted Light Inactivation technology to identify proteins involved in cancer cell spread, targeting HSP90A and CD155 molecules.
Hexaminolevulinate, a fluorescence-inducing compound, enables early detection of superficial bladder cancer lesions. This increases the five-year survival rate to 90% and reduces recurrence rates.
A new urinary marker, thymosin ß15, has been identified as a potential more accurate screening test for prostate cancer. When combined with PSA testing, it detects prostate cancer more often with fewer false-positives.
Patients with cancer have a significantly increased risk of developing venous thrombosis, with the risk highest in the first few months after diagnosis. The study found that patients with hematological, lung, or gastrointestinal cancers had a higher risk compared to those without cancer.
A new study found that blocking VEGFR-3 prevented lymphangiogenesis in a mouse model, potentially inhibiting tumor metastasis. The study suggests that targeting VEGFR-3 may be a viable therapeutic strategy to prevent lymphatic vessel growth and tumor spread.
A new technique detects lymph node metastases in cancer patients using nanoparticles and MRI, providing unprecedented accuracy and potentially sparing unnecessary surgery. The method involves tracking nodes with magnetic particles, identifying patterns for normal and malignant nodes, and generating a 3D reconstruction of the lymph nodes.
Research demonstrates that platelet aggregation and the release of LPA support bone metastases in breast cancer. Inhibiting platelet activity with Integrilin or targeting LPA signaling may slow tumor growth and reduce metastasis.
Individuals with obesity produce more toxic oxygen molecules that lead to changes in fat-derived hormones and contribute to the development of metabolic syndrome. Treatment with antioxidants reduces ROS production and improves diabetes symptoms.
Researchers tested a weakened version of herpes simplex virus against neuroblastoma tumors, with only the virus proving effective in treating the cancer. The study shows promise for using the therapy in children and potentially in other cancers as well.
Researchers at Scripps Research Institute use a class of compounds known as Src kinase inhibitors to stabilize blood vessels and block tumor cell metastasis. By increasing the protective barrier strength of host blood vessels, the approach prevents cancer cells from exiting the bloodstream, making them vulnerable to immune system attack.
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a critical molecular switch, GSK-3ß, that allows cancer cells to become mobile and move away from tumors. This discovery provides an anticancer strategy to pursue by boosting GSK-3ß activity, which can repress the ability of cancer to spread.
Researchers found that Hedgehog activity in localized prostate tumors is significantly lower than in metastatic cancers. Blocking the Hedgehog signal with cyclopamine slowed tumor growth and even reversed aggressive cancer progression in mice experiments.
A molecule called hepsin has been found to promote the deadly progression of prostate cancer by disrupting tissue organization. This discovery may lead to the development of new therapeutics designed to decrease the spread of prostate cancer.
A new study has found that patients with high levels of circulating tumor cells in their blood have shorter progression-free survival and overall survival rates compared to those with low levels. The presence of these cells can predict prognosis more accurately than other factors, allowing for more tailored treatment decisions.
Scientists at the Pacific Northwest Research Institute discovered evidence for DNA structure characteristic of metastasis in prostates with metastazing tumors. Early detection is crucial in fighting cancer, and this finding could lead to a new powerful weapon against cancer spread.
Scientists Gary Bokoch and colleagues discovered the mechanism by which Rac is released from RhoGDI, revealing a critical role for p21-activated kinase (Pak) in regulating cell motility. This breakthrough offers insights into tumor growth, immune responses, and neurological diseases.
Researchers discover that cancer cells misuse the Twist protein to bypass multiple steps of metastasis, a process that requires cell invasion and migration. The study suggests potential applications for developing a Twist inhibitor as a therapeutic approach.
The European Commission has approved the combination of Herceptin and Taxotere as a first-line treatment for HER2-positive breast cancer, significantly improving median life expectancy by over one-third. The therapy also showed high response rates, with 61% of patients responding to treatment.
Researchers have identified a protein, fibulin-5, that inhibits the sprouting of new blood vessels, which is crucial for cancer tumor growth. The findings suggest that fibulin-5 may be an effective cancer therapy and could also serve as a diagnostic tool to detect cancer status.
Researchers at Tufts University have discovered an extracellular form of heat shock protein 90 (hsp90) involved in cancer cell invasion, a key step in tumor progression. The study highlights the potential for developing antibodies against hsp90 as a new treatment option for cancer.
A new standard of care has been established for treating brain metastases, offering improved prognosis and quality of life for patients. Combining radiation therapy with different modalities shows significant benefits in managing this type of cancer.
A study identified four tumor gene expression patterns that may serve as biomarkers of prognosis for head and neck squamous cell cancer patients. The patterns were associated with different outcomes, including the worst outcome linked to epidermal growth factor pathway activation, and a tobacco exposure signature.
A study by the American College of Radiology found that thoracic PET scans are suitable for diagnosing some lung cancer patients with localized disease. This approach reduces radiation exposure and saves time compared to whole-body PET examinations, which cover a broader area of the body.
Researchers found higher plasma selenium levels are associated with a decreased risk of advanced prostate cancer, while DNAzymes targeting c-Jun may inhibit tumor growth. Glucocorticoid prescriptions are linked to an increased risk of skin cancers and non-Hodgkin's lymphoma.
Periostin is a protein that promotes metastatic growth of colon cancer by augmenting cell survival, and may be involved in the progression of other cancers. The study identified periostin as a potent promoter of late-stage tumor progression, highlighting its potential as a therapeutic target for preventing deadly metastatic cancers.
Researchers at the University of North Carolina identified the role of the K1 gene in tumor cell growth and metastasis, potentially leading to new treatment options. The study found that the K1 gene initiates cancerous processes by up-regulating growth factors and breaking down supporting tissue.
A new study found that women with ductal carcinoma in situ (DCIS) who undergo conservation treatment have a similar rate of survival compared to those who undergo mastectomy. Close monitoring and regular screenings are crucial for successful treatment and early detection of recurrence.